Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

europharma.dk aps - thiamazol - tabletter - 5 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

eql pharma ab - ondansetronhydrochloriddihydrat - filmovertrukne tabletter - 4 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Uni Eropa - Dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

panpharma - thiopentalnatrium og natriumcarbonat - pulver til injektionsvæske, opløsning - 0,5 g

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

panpharma - erythromycinlactobionat - pulver til infusionsvæske, opløsning - 500 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - clopidogrel (as hydrogen sulfate) - stroke; peripheral vascular diseases; myocardial infarction; acute coronary syndrome - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:- patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. - patienter, der lider af akut koronar syndrom:non-st-segment elevation akut koronar syndrom (ustabil angina pectoris eller non-q-tak myokardieinfarkt), herunder patienter, der gennemgår en stent placering efter perkutan koronar intervention, i kombination med acetylsalicylsyre (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi.